Singapore: Biopharmaceutical company Nanotherapeutics has selected GE Healthcare Life Sciences' FlexFactory biomanufactu...
Singapore: Chemical Heritage Foundation (CHF) and Biotechnology Industry Organization (BIO) have selected Mexican steroi...
Singapore: Austrianova Singapore has established a research cell bank, the first step towards late-phase clinical trials...
Singapore: Japanese companies Dainippon Sumitomo Pharma and Takeda Pharmaceutical have obtained approval for marketing a...
Singapore: Japan's Astellas Pharma has collaborated with US-based Ambrx for the discovery and development of novel antib...
Singapore: Jubilant Biosys, a subsidiary of Bangalore-based Jubilant Life Sciences, has expanded its drug discovery alli...
Singapore: Patrys completed initial treatment of second group of three patients in its phase I/IIa PAT-SM6 multiple myel...
Singapore: AstraZeneca's global biologics R&D arm, MedImmune, plans to acquire Amplimmune, which is a US-based biolo...
Singapore: Biostar Pharmaceuticals, a China-based manufacturer and marketer of pharmaceutical and health supplement prod...
Singapore: Japan-based Otsuka Pharmaceutical and H Lundbeck have received US FDA approval for Abilify Maintena (aripipra...
Singapore: Australia-based Novogen has acquired a novel drug technology that will be developed as a potentially major cl...
Singapore: US Food and Drug Administration (FDA) have issued a complete response letter regarding a supplemental New Dru...
Singapore: Sanofi and the Global Alliance for TB Drug Development (TB Alliance) entered a research collaboration to acce...
Lupin Pharmaceutical, which aims to be the best transnational pharmaceutical company in the world, stroked 10.64 percent...
Singapore: Australian drug delivery technology company Phosphagenics has appointed biotech industry veterans Mr Lawrence...
Singapore: Following successful first-in-man phase I and two phase IIa clinical studies with the oral formulation of fin...
Recent promising data on drug approvals in 2011 shows that there were 35 new molecular entities (NME) approved by the FD...
Singapore: Sweden-based Medivir has discontinued the development of its hepatitis B compound MIV-210 based on a joint de...
